Left atrial remodelling, mid-regional pro-atrial natriuretic peptide, and prognosis across a range of ejection fractions in heart failure

Aims Measures of structural and functional remodelling of the left atrium (LA) are emerging as useful biomarkers in heart failure (HF). We hypothesized that LA volume and its contribution to stroke volume (SV) would predict a composite endpoint of HF hospitalization or death in patients with HF. Methods and results We recruited 57 controls and 86 patients with HF, including preserved and reduced left ventricular ejection fraction (LVEF). Cardiac magnetic resonance imaging was used to evaluate LA volumes and contribution to LV SV. Plasma mid-region pro-atrial natriuretic peptide (MR-proANP) was evaluated. LA volume was negatively correlated with LVEF (P= 0.001) and positively correlated with LV mass in HFrEF (P<0.001) but not in HFpEF. LA volume at enddiastole was associated with the composite endpoint in HFrEF (hazard ratio 1.26, 95% confidence interval 1.01-1.54; P= 0.044), but not HFpEF (1.06, 0.85-1.30; P= 0.612), per 10 mUm increase. Active contribution to SV was negatively associated with the composite endpoint in HFpEF (0.32, 0.14-0.66; P=0.001), but not HFrEF (0.91, 0.38-2.1; P=0.828) per 10% increase. MR-proANP was associated with the composite endpoint in HFpEF (1.46, 1.03-1.94; P= 0.034), but not in HFrEF (1.14, 0.88-1.37; P= 0.278), per 100 pM increase. Conclusion We found different relationships between LA remodelling and biomarkers in HFrEF and HFpEF. Our results support the hypothesis that the pathophysiologic underpinnings of HFpEF and HFrEF are different, and atrial remodelling encompasses distinct components for each HF subtype.

Automated summary

The study revealed distinct relationships between left atrial remodeling and biomarkers in patients with HFpEF and HFrEF, indicating different pathophysiologic mechanisms underlying the two HF subtypes. The findings suggest that left atrial remodeling may have unique implications for HFpEF and HFrEF.